E2609
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Alzheimer's Disease
Conditions
Early Alzheimer's Disease
Trial Timeline
Aug 1, 2016 → Jan 25, 2017
NCT ID
NCT02859207About E2609
E2609 is a phase 1 stage product being developed by Eisai for Early Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02859207. Target conditions include Early Alzheimer's Disease.
What happened to similar drugs?
1 of 20 similar drugs in Early Alzheimer's Disease were approved
Approved (1) Terminated (1) Active (18)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02859207 | Phase 1 | Completed |
| NCT01975636 | Phase 1 | Completed |
| NCT01716897 | Phase 1 | Completed |
Competing Products
20 competing products in Early Alzheimer's Disease